Vigonvita Life Sciences Co., Ltd., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its lead products include LV232, a first-in-class dual-target serotonin transporter/5-hydroxytryptamine 3 receptor modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction. The company also develops VV116, a RdRp inhibitor completed a Phase II clinical trial for the treatment of respiratory syncytial virus infection; TPN102, a voltage-gated sodium and calcium channels inhibitor, which is in Phase I clinical trial for the treatment epilepsy; VV119, a multi-target serotonin-dopamine activity modulator, which is in Phase I clinical trial for the treatment of psychiatric disorders and schizophrenia; VV261, an antiviral nucleoside prodrug, which is in Phase I clinical trial for RNA viruses, including coronavirus, influenza virus, arenavirus, and RSV. In addition, its preclinical products include VV147, a small molecule drug candidate that regulates the glutamatergic system for the treatment of depression; VV913, a small molecule with a novel structure designed for regulating the monoaminergic system to treat premature ejaculation; and VV207, an orally administered nucleoside prodrug with a novel structure, exhibiting broad-spectrum antiviral activity against DNA viruses. The company was incorporated in 2013 and is headquartered in Suzhou, China.